



DIAGNOSTIC AND THERAPEUTIC CENTER OF ATHENS "HYGEIA SA"
 SA Registration No. 13165/06/B/86/14
 4 KIFISIAS AVENUE & ERYTHROU STAVROU STR., 15123 MAROUSI, ATHENS
 Data and information for the period from January 1 2009 to March 31 2009
 (according to Decision 4/507/28.04.2009 of the BoD of HCMC)

The following condensed statements, notes and information aim to provide a general update on the financial position and the results of "HYGEIA S.A." Group and the parent Company. We therefore, recommend to the reader, before making any investment decision or any other transaction with the publisher, to refer to the publisher's internet address, where the financial statements are attached along with the review report of the auditors where appropriate

GENERAL INFORMATION					INCOME STATEMENT (Amounts in Euros)																						
Company's web address: www.hygeia.gr					Group Company																						
Approval date of the 1Qqrter 2009 financial Statements by Board of Directors: May 22, 2009					01/01-31/03/2009 01/01-31/03/2008 01/01-31/03/2009 01/01-31/03/2008																						
BALANCE SHEET (Amounts in Euros)					STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD (Amounts in Euros)																						
					Group Company																						
					31/03/2009 31/12/2008 31/03/2009 31/12/2008																						
ASSETS					Net worth in the beginning of the period (01.01.2009 and 01.01.2008 respectively)																						
Tangible assets	241.626.616	233.278.633	103.375.135	101.672.447	379.095.531	358.480.635	324.316.483	329.791.544																			
Investments in property	168.672	169.314	168.672	169.314																							
Intangible assets	138.924.913	139.817.825	3.477.333	3.679.886																							
Other non-current assets	242.338.013	241.536.502	372.197.054	371.049.131																							
Inventories	10.924.275	9.854.756	2.202.272	2.183.995																							
Trade and other receivables	103.341.750	89.362.194	51.547.780	42.933.193																							
Other Current Assets	106.761.847	199.576.107	94.138.013	189.807.965																							
TOTAL ASSETS	844.086.087	913.595.331	627.106.259	711.495.931																							
SHAREHOLDERS EQUITY & LIABILITIES					Total Comprehensive Income for the period after tax																						
Share capital	51.508.673	51.508.673	51.508.673	51.508.673	6.802.559	5.471.571	3.798.030	1.627.871																			
Other equity items of Company shareholders	286.047.936	288.632.091	275.587.373	272.807.810																							
Total net worth of Company shareholders (a)	337.556.609	340.140.765	327.096.046	324.316.483																							
Minority Interest (b)	36.348.109	38.954.767	0	0																							
Total Net worth (c) = (b) + (a)	373.904.718	379.095.531	327.096.046	324.316.483																							
Long-term Debt	30.811.322	33.135.331	0	0																							
Provisions & other Long-term liabilities	71.919.776	73.153.275	17.699.321	19.320.025																							
Short-term bank debt	252.931.220	328.778.624	230.000.000	312.953.140																							
Other short-term liabilities	114.519.051	99.432.570	52.310.891	54.906.283																							
Total liabilities (d)	470.181.369	534.499.800	300.010.213	387.179.448																							
TOTAL SHAREHOLDERS EQUITY & LIABILITIES (c) + (d)	844.086.087	913.595.331	627.106.259	711.495.931																							
CASH FLOW STATEMENT (Amounts in Euros)					Additional Notes & Information																						
					1. The companies that are included in the consolidation (Group Structure) are included in Note 5 & 10 of the 1Q09 financial statements. The consolidated financial statements include the following companies: a) The 100% subsidiary company "Obstetrics & Gynaecology Clinic Evangelimos Ltd" that controls directly the companies " Evangelimos Management Ltd", "AKESO KTIMITIKI" and "Evangelimos KTIMITIKI Ltd" with 60% stake since it assumed control on 7.7.2008 b) The company "STEM HEALTH UNIREA S.A.", that HYGEIA controls indirectly 25% and through its subsidiary company 50% of "STEM HEALTH S.A." since it assumed control on 18.9.2008 c) the "Genesis Holding A.S." Group that HYGEIA S.A controls directly 50% since it assumed control on 8.12.2008 and d) the company "MAGNETIC HYGEIA DIAGNOSTIC IMAGING S.A.", is consolidated with the method of full consolidation for the first time, because of the stake increase during March 2009, from 20% to 100% of its share capital. The above-mentioned companies, are included in the consolidated financial statements of HYGEIA Group for the period 01.01.2009-31.03.2009 and were not included the same period of 2008. During the current period MITERA S.A. increased its stake in the subsidiaries companies LETO HOLDINGS S.A and LETO S.A and as a result its participation increased from 73.83% to 88.62% and from 32.90% to 43.99% respectively. Hence, the indirect stake of D.T.C.A HYGEIA S.A in the abovementioned companies increased from 72.76% to 87.34% and from 69.11% to 87.39% respectively. 2. During the 3Q2008, was concluded the evaluation of the assets fair value, the recognized intangible assets and liabilities that were obtained from "MITERA Group SA" during the fiscal year 2007. Based on the values that arose from the evaluation was conducted allocation of the acquisition cost to the respective accounts and respectively was reduced the initial recognized goodwill. As a result, the Income Statement and the Balance Sheet of the Group for the fiscal year 31.12.2008 and the period 31.3.2008 were restated. Reference in Note 21 of the interim financial statements notes. 3. DTCA HYGEIA S.A BoD on its 2.12.2008 meeting, taking under consideration the circumstances in S.E.E, unanimously decides to proceed within the early full redemption of the Convertible Bond Loan on its first call (10.01.2009) based on the terms of the Information Memorandum. On 13.01.2009 the company paid the full amount that corresponds in the full early redemption EUR 306.015.300 calculated according to the terms on the 102% of the issued price. 4. On January 22, 2009 the A' Repeated Extraordinary General Meeting of the Shareholder, with majority of 99.9% of the participation decided the increase of the Company's share capital by payment in cash, with a priority right in favor of existing shareholders by issuing 37,689,273 new common registered shares with nominal value Euro 0.41 each, at a price of Euro 2.20 per share, by cash payment and priority rights to existing shareholders, and the amendment of Article 5 the Company's Articles of Association. The total of the raised funds through the aforementioned increase amounted to €82,916,400.60. The shareholders on the ex- date will have the right for 3 new shares corresponding to 10 old ones. The raised funds will be used to cover part of the EUR 300 mil that were paid to the Bondholders, for the early redemption of the convertible bond loan The company will proceed to revocation of the abovementioned A' Repeat Extraordinary General Meeting of the Shareholder, regarding the Company's Share Capital Increase, due to regulatory reasons. According to 27.04.2009 Invitation to Ordinary General Meeting, the A' Repeat Extraordinary General Meeting of the Shareholder shall convene on Wednesday, 03 June 2009, to decide about the Company's Share Capital Increase 5. The most important sub judge, the juridical decisions that have or may have important effect in the economic situation or in the operation of the Company and the Group amount circa € 58.2m and € 118m respectively, and they have to do with patients' or their heirs requirements, part of the abovementioned amount is covered by Mal Practice insurance. The company has made a cumulative provision of EUR 2.5m for litigation. The amount of equivalent provision for the group is circa EUR 10.4m. Substantial surcharges from other litigious or under arbitration disputes and decisions of judicial instruments exceeding the provision already made are not expected to arise. 6. The company made a cumulative provision of EUR675 thousand for unaudited fiscal years. The amount of equivalent provision for the group is circa EUR 1.3m. The related analysis for the company's unaudited fiscal years is in the interim Financial Notes, note 17. 7. There are no provisions according to paragraphs 10,11 and 14 of the IAS 37 article " Provisions, Possible Liabilities and Possible assets" for the Group and the Company. 8. On 31.03.2009, the Group's personnel amounted 4,185 individuals (31.03.2008: 2,294) and the company's personnel amounted to 1,136 (31.03.2008: 1,069), respectively. 9. The cumulative amounts of the company's and the group's revenues/ expenses from and to affiliated parties from the beginning of the fiscal year 2008, according to IAS 24, are presented in the following table: <table border="1"> <thead> <tr> <th></th> <th>Group</th> <th>Company</th> </tr> </thead> <tbody> <tr> <td>a) Revenues</td> <td>7,491</td> <td>108,002</td> </tr> <tr> <td>b) Expenses</td> <td>0</td> <td>5,631,016</td> </tr> <tr> <td>c) Receivables</td> <td>11,892,259</td> <td>6,109,046</td> </tr> <tr> <td>d) Liabilities</td> <td>17,882,437</td> <td>24,832,072</td> </tr> <tr> <td>e) Transactions and payments of senior executives and administration members</td> <td>930,181</td> <td>407,786</td> </tr> </tbody> </table> 10. There are pledges on the Group's assets for € 13.1m there are no pledges on the Company's assets 11. In the direct changes of the shareholders equity of the Group, EUR 1,161,540 is expenses from the earlier redemption of the company's convertible bond loan. 12. The other total revenues for the period 01.01-31.03.2009 amounts to (€1,322,428) and concerns exchanges differences from the conversion of the subsidiaries' financial statements to Euro. Respectively, for the period 01.01-31.03.2008 other total revenues amounts to (€ 14.461). 13. The Parent's and the Group's Financial Statements of 31.03.2009, were approved by the company's Board of Directors on 22.05.2009. 14. The Company followed the basic accounting principles of the annual financial statements for the fiscal year 2008, except of the case that is reported in note 3.2 of the interim financial statements. We mention, that there is an earlier implementation on IFRS 3, IAS 27 & 28 and adoption of the amendment IAS 1 & 23 and IFRS 8.						Group	Company	a) Revenues	7,491	108,002	b) Expenses	0	5,631,016	c) Receivables	11,892,259	6,109,046	d) Liabilities	17,882,437	24,832,072	e) Transactions and payments of senior executives and administration members	930,181	407,786
	Group	Company																									
a) Revenues	7,491	108,002																									
b) Expenses	0	5,631,016																									
c) Receivables	11,892,259	6,109,046																									
d) Liabilities	17,882,437	24,832,072																									
e) Transactions and payments of senior executives and administration members	930,181	407,786																									
Operating activities	10.384.098	7.890.968	3.979.675	2.407.042																							
Plus / minus adjustments for:																											
Depreciations	4.688.646	3.463.148	1.789.542	1.676.940																							
Provisions	967.859	676.027	456.429	238.235																							
Income from use of provisions for previous periods	(8.797)	0	0	0																							
Results (Income, expenses, earnings and losses) from investment activities	(2.014.353)	(1.916.015)	(1.094.920)	(1.829.137)																							
Depreciations of subsidies	0	(8.729)	0	0																							
Profit / (Loss) from associate companies	20.568	(43.693)	0	0																							
Interest Expenses	4.708.368	6.414.943	3.825.399	5.623.858																							
Other	143.073	0	143.073	0																							
Plus / minus adjustments for changes in working capital accounts or changes related to operating activities:																											
Decrease / (increase) in other Long-term receivables	(1.903)	(2.765.251)	(3.024)	(2.678.634)																							
Decrease / (increase) in inventories	(1.097.075)	117.418	(18.277)	195.462																							
Decrease / (increase) in receivables	(18.152.517)	(13.920.900)	(4.493.215)	(7.045.852)																							
(Decrease) / Increase in liabilities (minus banks liabilities)	8.261.993	4.502.959	(1.120.342)	(510.870)																							
Decrease / (Increase) of Provisions	(344.366)	(107.125)	(346.808)	(107.125)																							
Minus:																											
Interests expenses and relevant expenses paid	(5.935.840)	(1.317.338)	(5.052.871)	(832.092)																							
Tax Paid	(370.800)	0	(119.780)	0																							
Total inflow / (outflow) from operating activities (a)	1.248.954	2.986.412	(2.055.121)	(2.862.173)																							
Investment activities																											
Acquisition of subsidiaries, associates, ventures and other investments	(8.062.332)	(6.587.983)	(5.762.928)	(9.912.585)																							
Purchase of tangible and intangible fixed assets	(12.003.859)	(3.652.556)	(3.289.034)	(1.912.263)																							
Revenues from the sale of tangible and intangible fixed assets	0	0	(4.041.549)	0																							
Loans to associated companies	0	0	(4.041.549)	0																							
Acquisition of reserves for sale financial assets	0	(58.691)	0	0																							
Interests Received	1.829.605	90.586	968.200	3.708																							
Dividends Received																											
Total inflow / (outflow) from investment activities (b)	(18.236.586)	(10.208.644)	(12.125.312)	(11.821.140)																							
Financing activities																											
Share Capital Increase Receivables																											
Net inflows/(outflows) of loans	227.617.843	311.029.794	220.000.000	306.974.386																							
Payments of loans	(302.661.409)	(49.703.409)	(301.489.519)	(42.252.481)																							
Payments of liabilities from financing leases (sinking funds)	(699.652)	(325.474)	0	(36.847)																							
Dividends Paid																											
Total inflow / (outflow) from financing activities (c)	(75.743.218)	261.000.911	(81.489.519)	264.685.059																							
Total increase / (decrease) in cash flow and cash equivalents of the period (a) + (b) + (c)	(92.730.850)	253.778.679	(95.669.952)	250.001.746																							
Cash and cash equivalents in the beginning of the period	199.576.107	8.870.649	189.807.965	3.924.669																							
Effect of changes in exchange rates	(83.409)	0	0	0																							
Cash and cash equivalents at the end of the period	106.761.848	262.649.329	94.138.013	253.926.414																							
Maroussi, May 22 2009																											
THE BoD CHAIRMAN	THE CHIEF EXECUTIVE OFFICER	GROUP CFO	THE DEPUTY CFO	THE HEAD ACCOUNTANT																							
KON. STAVROU	THEM. CHARAMIS	PANT. DIMOPOULOS	EL. KELEPOURI	G. NOMIKOS																							
ID No. A 049114	ID No. AB340781	ID No. AB606210	ID No. Σ 028050	ID No. Σ 014543																							